ValuEngine Lowers CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to Sell
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Separately, Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of CASI Pharmaceuticals in a report on Friday, March 31st.
Shares of CASI Pharmaceuticals (NASDAQ CASI) opened at 1.05 on Friday. The company’s market cap is $63.21 million. CASI Pharmaceuticals has a one year low of $0.91 and a one year high of $1.76. The company has a 50 day moving average price of $1.03 and a 200 day moving average price of $1.20.
CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Equities research analysts expect that CASI Pharmaceuticals will post ($0.24) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/22/valuengine-lowers-casi-pharmaceuticals-inc-nasdaqcasi-to-sell.html.
An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC increased its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 103.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 124,800 shares of the biotechnology company’s stock after buying an additional 63,500 shares during the period. Renaissance Technologies LLC owned about 0.21% of CASI Pharmaceuticals worth $144,000 as of its most recent SEC filing. 3.90% of the stock is owned by institutional investors and hedge funds.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.